Published in Curr Opin Rheumatol on November 01, 2014
The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med (2016) 0.78
Predictors of Reduced Health-Related Quality of Life in Adult Patients with Idiopathic Inflammatory Myopathies. Arthritis Care Res (Hoboken) (2017) 0.75
Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) (1977) 4.79
A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) (1991) 4.01
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum (2013) 3.55
Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum (2011) 2.99
Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum (2004) 2.31
US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum (2003) 2.21
Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum (2009) 1.94
A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum (2006) 1.93
Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol (2002) 1.83
The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol (2011) 1.80
Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) (2005) 1.79
An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med (2007) 1.79
New-onset juvenile dermatomyositis: comparisons with a healthy cohort and children with juvenile rheumatoid arthritis. Arthritis Rheum (1997) 1.78
International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum (2005) 1.75
Defining Clinical Improvement in Adult and Juvenile Myositis. J Rheumatol (2003) 1.75
TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum (2000) 1.71
Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum (2003) 1.71
Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr (2006) 1.71
Long-term observational study of sporadic inclusion body myositis. Brain (2011) 1.69
Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol (2008) 1.67
International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum (2004) 1.66
Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) (2004) 1.66
Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) (2010) 1.65
A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol (2011) 1.64
Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum (2008) 1.60
History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum (2005) 1.58
Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum (2012) 1.54
Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) (2010) 1.49
Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken) (2010) 1.48
Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) (2002) 1.47
The plasma cell signature in autoimmune disease. Arthritis Rheumatol (2014) 1.47
Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol (2008) 1.44
Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther (2007) 1.40
Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) (2014) 1.39
Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) (2006) 1.39
Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc (2013) 1.37
Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum (2009) 1.37
Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum (2011) 1.36
Quality of life in dermatomyositis. J Am Acad Dermatol (2011) 1.34
Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. Ann Rheum Dis (2008) 1.34
The evolution of biobanking best practices. Clin Chim Acta (2012) 1.34
Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum (2009) 1.30
Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. J Rheumatol (2001) 1.29
Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum (2013) 1.27
The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) (2006) 1.25
Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) (2010) 1.25
Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res (Hoboken) (2012) 1.25
Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken) (2013) 1.24
Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum (2006) 1.24
In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther (2006) 1.23
Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) (2010) 1.23
Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) (2008) 1.22
Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken) (2012) 1.20
The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) (2013) 1.19
The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) (2007) 1.18
Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians. Medicine (Baltimore) (2005) 1.18
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis (2012) 1.15
Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther (2011) 1.14
Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum (2013) 1.12
Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument. Br J Dermatol (2009) 1.12
Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One (2012) 1.11
The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) (2013) 1.10
Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry (2008) 1.10
Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) (2009) 1.09
Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum (2008) 1.07
Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol (1998) 1.07
Pulmonary outcome in juvenile dermatomyositis: a case-control study. Ann Rheum Dis (2010) 1.07
Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) (2008) 1.07
Familial aggregation of autoimmune disease in juvenile dermatomyositis. Pediatrics (2011) 1.06
Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum (2010) 1.05
The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken) (2010) 1.05
Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? Arthritis Res Ther (2013) 1.04
Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol (2011) 1.04
Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum (2009) 1.03
The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients. Arthritis Rheum (2008) 1.02
Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: Relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine (2010) 1.00
HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum (2006) 1.00
Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve (2012) 1.00
Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore) (2012) 0.99
Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study. Ann Rheum Dis (2011) 0.98
Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care Res (Hoboken) (2014) 0.98
Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. Intern Med J (2012) 0.97
Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) (2010) 0.97
Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data? Neurology (2013) 0.97
Recent advances in the immunogenetics of idiopathic inflammatory myopathy. Arthritis Res Ther (2011) 0.97
Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J (2009) 0.96
Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology (Oxford) (2010) 0.96
Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM. J Invest Dermatol (2012) 0.96
Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype. Neuromuscul Disord (2009) 0.94
Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford) (2011) 0.94
A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol (2010) 0.93
Immunopathogenesis of juvenile dermatomyositis. Muscle Nerve (2010) 0.93
Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case-control study. Arthritis Care Res (Hoboken) (2010) 0.93
The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum (2008) 0.92
Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology (Oxford) (2012) 0.92
Juvenile dermatomyositis calcifications selectively displayed markers of bone formation. Arthritis Rheum (2009) 0.92
Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther (2011) 0.92
Gene expression profiles from discordant monozygotic twins suggest that molecular pathways are shared among multiple systemic autoimmune diseases. Arthritis Res Ther (2011) 0.92
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09
Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res (2009) 3.81
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum (2013) 3.55
Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum (2004) 2.31
Age-related somatic structural changes in the nuclear genome of human blood cells. Am J Hum Genet (2012) 2.15
Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum (2012) 2.09
A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum (2006) 1.93
International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum (2005) 1.75
Defining Clinical Improvement in Adult and Juvenile Myositis. J Rheumatol (2003) 1.75
Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol (2008) 1.67
International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum (2004) 1.66
Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) (2010) 1.65
Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum (2008) 1.60
Association of systemic and thyroid autoimmune diseases. Clin Rheumatol (2005) 1.48
HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. Arthritis Rheum (2003) 1.46
Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA (2011) 1.41
Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) (2006) 1.39
Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum (2009) 1.30
Paraneoplastic rheumatic syndromes. Rheumatol Int (2005) 1.30
Vitamin D and autoimmune thyroid diseases. Cell Mol Immunol (2011) 1.28
Mechanisms of disease: Environmental factors in the pathogenesis of rheumatic disease. Nat Clin Pract Rheumatol (2007) 1.24
Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum (2006) 1.24
Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) (2008) 1.22
Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum (2003) 1.21
The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) (2013) 1.19
Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians. Medicine (Baltimore) (2005) 1.18
Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci (2005) 1.18
Occupational exposures and autoimmune diseases. Int Immunopharmacol (2002) 1.16
The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) (2013) 1.10
Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthritis Rheum (2008) 1.09
Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol (2007) 1.03
Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum (2009) 1.03
UV radiation regulates Mi-2 through protein translation and stability. J Biol Chem (2008) 1.02
Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum (2002) 1.01
Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: Relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine (2010) 1.00
HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum (2006) 1.00
Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore) (2012) 0.99
A comparative study of arterial stiffness, flow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases. Clin Rheumatol (2009) 0.98
Possible roles and determinants of microchimerism in autoimmune and other disorders. Autoimmun Rev (2004) 0.98
Diagnostic criteria for polymyositis and dermatomyositis. Lancet (2003) 0.97
Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) (2010) 0.97
Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol (2014) 0.97
Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J (2009) 0.96
Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J (2009) 0.95
Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. Arthritis Rheum (2008) 0.94
Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis (2006) 0.93
Alternative scoring of the Cutaneous Assessment Tool in juvenile dermatomyositis: results using abbreviated formats. Arthritis Rheum (2008) 0.93
Autoantibodies as predictive and diagnostic markers of idiopathic inflammatory myopathies. Autoimmunity (2004) 0.92
Gene expression profiles from discordant monozygotic twins suggest that molecular pathways are shared among multiple systemic autoimmune diseases. Arthritis Res Ther (2011) 0.92
Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. Arthritis Rheum (2007) 0.91
Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy. Arthritis Rheum (2007) 0.91
Microstructure and mineral composition of dystrophic calcification associated with the idiopathic inflammatory myopathies. Arthritis Res Ther (2009) 0.90
Seasonal influence on the onset of idiopathic inflammatory myopathies in serologically defined groups. Arthritis Rheum (2005) 0.90
Childhood socioeconomic factors and perinatal characteristics influence development of rheumatoid arthritis in adulthood. Ann Rheum Dis (2012) 0.90
Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages. Arthritis Res Ther (2006) 0.88
Genetic risk and protective factors for the idiopathic inflammatory myopathies. Curr Rheumatol Rep (2009) 0.88
Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. Arthritis Rheum (2011) 0.87
Accommodating measurements below a limit of detection: a novel application of Cox regression. Am J Epidemiol (2014) 0.86
Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. Arthritis Rheum (2004) 0.86
Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. Arthritis Rheum (2013) 0.85
Mass spectrometric determination of IgG subclass-specific glycosylation profiles in siblings discordant for myositis syndromes. J Proteome Res (2011) 0.84
Evaluation of oral manifestations and masticatory force in patients with polymyositis and dermatomyositis. J Oral Pathol Med (2005) 0.84
HLA type and immune response to Borrelia burgdorferi outer surface protein a in people in whom arthritis developed after Lyme disease vaccination. Arthritis Rheum (2009) 0.83
Immunogenetic risk and protective factors for the development of L-tryptophan-associated eosinophilia-myalgia syndrome and associated symptoms. Arthritis Rheum (2009) 0.83
Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) (2014) 0.82
Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population. Immunol Res (2013) 0.82
Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. Clin Chem (2002) 0.82
[Myositis associated with tumors]. Magy Onkol (2002) 0.82
State of the art: what we know about infectious agents and myositis. Curr Opin Rheumatol (2011) 0.82
Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups. Open Rheumatol J (2012) 0.82
Ferritin and prolactin levels in multiple sclerosis. Isr Med Assoc J (2011) 0.81
Metabolic abnormalities and cardiovascular risk factors in children with myositis. J Pediatr (2009) 0.81
HMGB1 expression and muscle regeneration in idiopathic inflammatory myopathies and degenerative joint diseases. J Muscle Res Cell Motil (2015) 0.81
Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis--a prospective case-series study. Arthritis Res Ther (2013) 0.80
Xenotropic murine leukemia virus-related virus is not associated with chronic fatigue syndrome in patients from different areas of the us in the 1990s. Virol J (2011) 0.80
Plasma proteomic profiles from disease-discordant monozygotic twins suggest that molecular pathways are shared in multiple systemic autoimmune diseases. Arthritis Res Ther (2011) 0.79
Genomic organization, transcriptional mapping, and evolutionary implications of the human bi-directional histidyl-tRNA synthetase locus (HARS/HARSL). Biochem Biophys Res Commun (2002) 0.78
Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. Clin Exp Rheumatol (2014) 0.78
Primary lung adenocarcinoma associated with anti-Jo-1 positive polymyositis. Joint Bone Spine (2010) 0.77
Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: are current therapies just scratching the surface? Arthritis Rheum (2010) 0.77
[Inclusion body myositis]. Ideggyogy Sz (2015) 0.77
Detection of TT virus in patients with idiopathic inflammatory myopathies. Ann N Y Acad Sci (2005) 0.77
Associations Between Selected Xenobiotics and Antinuclear Antibodies in the National Health and Nutrition Examination Survey, 1999-2004. Environ Health Perspect (2015) 0.76
Prevalence of antiphospholipid and antinuclear antibodies in children with epilepsy. Med Sci Monit (2009) 0.76
Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy. Arthritis Care Res (Hoboken) (2013) 0.76
Serum proteins and paraproteins in women with silicone implants and connective tissue disease: a case-control study. Arthritis Res Ther (2007) 0.75
On Determining the Effects of Therapy on Disease Damage in Non- randomized Studies with Multiple Treatments: A study of Juvenile Myositis. Commun Stat Theory Methods (2009) 0.75
Applicability of the paediatric rheumatology international trials organisation disease activity core set for juvenile dermatomyositis: comment on the article by Ruperto et al. Arthritis Rheum (2008) 0.75
Post-zygotic and inter-individual structural genetic variation in a presumptive enhancer element of the locus between the IL10Rβ and IFNAR1 genes. PLoS One (2013) 0.75
An unusual association: anti-Jo1 and anti-SRP antibodies in the serum of a patient with polymyositis. Clin Rheumatol (2010) 0.75
Prostate cancer underlying acute, definitive dermatomyositis: successful treatment with radical perineal prostatectomy. Clin Rheumatol (2005) 0.75
Antiphospholipid syndrome accompanied by a silent splenic infarct in a patient with juvenile SLE. Rheumatol Int (2006) 0.75
[Polymyositis/scleroderma autoantibody-positive scleroderma with dermatomyositis (scleromyositis)]. Orv Hetil (2002) 0.75
[Comparison of clinical characteristics and laboratory parameters of patients with dermatomyositis-specific autoantibodies and autoantibody-negative patients]. Orv Hetil (2015) 0.75
Rare, late complications in a patient with Hodgkin's disease. Haematologia (Budap) (2002) 0.75
[Clinical characteristics of juvenile dermatomyositis]. Orv Hetil (2003) 0.75
Antiphospholipid and antisynthetase syndrome in a patient with polymyositis-rheumatoid arthritis overlap. Clin Rheumatol (2004) 0.75
[Shared and distinctive characteristics of systemic autoimmune disorders]. Orv Hetil (2007) 0.75